Earnings
Carlsmed Raises Outlook To $78 Million–$80 Million But Defends Caution On Faster Growth
Analysts pressed management on reimbursement gains and new spine products as procedure volume grew 76% from a year earlier.
Carlsmed (CARL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Analysts pressed management on reimbursement gains and new spine products as procedure volume grew 76% from a year earlier.
SEC Filings
Surgeon adoption expanded, but executive-transition and legal costs helped push quarterly expenses to $29.4 million.